Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.01.138PMID 12637461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aromatase inhibitor development for treatment of breast cancer

  2004cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Preliminary data from ongoing adjuvant aromatase inhibitor trials.

  2001cited by this paper
• Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.

  2001cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.

  2001cited by this paper
• Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Antiestrogens: Mechanisms of action and resistance in breast cancer

  1997cited by this paper
• Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

  1997cited by this paper
• Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.

  1997cited by this paper
• A review of endocrine options for the treatment of advanced breast cancer.

  1997cited by this paper
• Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.

  1996cited by this paper
• Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.

  1996cited by this paper
• Proper sequence of endocrine therapies in advanced breast cancer.

  1996cited by this paper
• In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

  1995cited by this paper
• Use of tamoxifen for breast cancer: twenty-eight years later.

  1995cited by this paper
• Current perspectives on aromatase inhibitors in breast cancer.

  1994cited by this paper
• Tamoxifen withdrawal responses — chance observations or clinical clues to antioestrogen resistance?

  1994cited by this paper
• Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer.

  1993cited by this paper
• Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Italian Cooperative Group.

  1993cited by this paper
• Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

  1992cited by this paper
• Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.

  1992cited by this paper
• Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality.

  1991cited by this paper
• Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

  1990cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.

  1989cited by this paper
• Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

  1988cited by this paper
• Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

  1988cited by this paper
• Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.

  1987cited by this paper
• Prolonging tamoxifen therapy for primary breast cancer: findings from the national surgical adjuvant breast and bowel project clinical trial

  1987cited by this paper
• Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.

  1987cited by this paper
• The Stockholm trial on adjuvant tamoxifen in early breast cancer

  1987cited by this paper
• Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.

  1987cited by this paper
• Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.

  1986cited by this paper
• Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.

  1986cited by this paper
• Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer.

  1985cited by this paper
• Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.

  1985cited by this paper
• Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.

  1985cited by this paper
• Aminoglutethimide in the treatment of advanced breast cancer.

  1984cited by this paper
• TAMOXIFEN AND AMINOGLUTETHIMIDE IN ADVANCED BREAST CANCER

  1982cited by this paper
• A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

  1981cited by this paper
• Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy

  1980cited by this paper
• Aminoglutethimide in treatment of metastatic breast carcinoma.

  1978cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer

  1974cited by this paper
• Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.

  1974cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials

  2025cites this paper
• The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials

  2025cites this paper
• Standardized Definitions for Efficacy End Points for Adjuvant Trials-The Updated STEEP Criteria.

  2024cites this paper
• Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

  2024influential citation
• The future of clinical trials—goals, ideas, and discussion

  2024cites this paper
• Explained variation and degrees of necessity and of sufficiency for competing risks survival data

  2024cites this paper
• Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer

  2022cites this paper
• Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

  2021cites this paper
• Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.

  2021cites this paper
• ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

  2021cites this paper
• ERR α promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors

  2020cites this paper
• Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

  2020cites this paper
• Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

  2019cites this paper
• Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

  2019cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Valor pronóstico del análisis de marcadores moleculares mediante proteómica dirigida en cáncer de mama precoz con receptores hormonales positivos

  2018cites this paper
• ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors

  2018cites this paper
• Clinical utility of gene-expression signatures in early stage breast cancer

  2017cites this paper
• Optimal duration of adjuvant endocrine therapy: how to apply the newest data

  2017cites this paper
• Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

  2017cites this paper
• A retrospective study exploring clinical, biological and behavioural factors contributing to changes in body weight following early breast cancer diagnosis

  2017influential citation
• InforMatrix Aromatase Inhibitors in Breastcancer

  2016cites this paper
• Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2015cites this paper
• The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer

  2015cites this paper
• Analysis of the PI 3 K pathway in breast cancer

  2015influential citation
• Status of adjuvant endocrine therapy for breast cancer

  2014cites this paper
• Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients

  2014influential citation
• The Association Between Adiposity and Breast Cancer Recurrence and Survival: A Review of the Recent Literature

  2014cites this paper
• Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

  2013cites this paper
• The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

  2013cites this paper
• The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

  2013cites this paper
• Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

  2013cites this paper
• Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

  2012cites this paper
• EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

  2012cites this paper
• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  2011cites this paper
• Imaging , Diagnosis , Prognosis A New Molecular Predictor of Distant Recurrence in ER-Positive , HER 2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  2011cites this paper
• Conventional Clinical Risk Factors HER 2-Negative Breast Cancer Adds Independent Information to A New Molecular Predictor of Distant Recurrence in ER-Positive

  2011cites this paper
• A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.

  2011cites this paper
• Neue Entwicklungen in der endokrinen Therapie des prämenopausalen Mammakarzinoms

  2010cites this paper
• Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.

  2010cites this paper
• Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor–Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy

  2009cites this paper
• Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer

  2009influential citation
• Comparativereviewof anastrozole,letrozoleand exemestaneinthemanagement ofearlybreastcancer

  2009cites this paper
• Endokrine Therapie des Mammakarzinoms

  2009cites this paper
• Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

  2008cites this paper
• Aromatase inhibitors: past, present and future in breast cancer therapy

  2008influential citation
• Aromatase inhibitors in the management of early breast cancer.

  2008cites this paper
• Long-term safety of aromatase inhibitors in the treatment of breast cancer

  2008cites this paper
• Overcoming recurrence risk: extended adjuvant endocrine therapy.

  2008cites this paper
• The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias

  2008cites this paper
• Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

  2008influential citation
• Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence

  2008cites this paper
• Hormonal therapy for postmenopausal breast cancer: the science of sequencing

  2007cites this paper
• Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials

  2007influential citation
• Aromatase inhibitors for breast cancer

  2007cites this paper
• Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

  2007cites this paper
• Extended adjuvant therapy for breast cancer--how much is enough?

  2007cites this paper
• Tratamiento anti-hormonal adyuvante en mujeres post-menopáusicas con diagnóstico de carcinoma de mama

  2006cites this paper
• Extended adjuvant therapy with letrozole: reducing the risk of recurrence

  2006cites this paper
• The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.

  2006cites this paper
• Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer

  2006cites this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cites this paper
• Adjuvant endocrine therapy.

  2004cites this paper
• Effects of estrogen deprivation due to breast cancer treatment.

  2004cites this paper
• A review of adjuvant hormonal therapy in breast cancer.

  2004cites this paper
• Shifting paradigms in hormonal therapy for breast cancer

  2004cites this paper
• Impact of pretreatment thrombocytosis on survival in primary breast cancer

  2003cites this paper